Anthera Pharmaceuticals
San Mateo, CA
Anthera Pharmaceuticals is a pharmaceutical development company focused on the development and advancement of promising clinical products for the treatment of serious inflammatory diseases. Anthera's lead products have the potential to address a variety of inflammatory diseases including: acute lung injury, acute respiratory distress syndrome, acute chest syndrome, acute coronary syndrome, atherosclerosis, chronic obstructive pulmonary disease and psoriasis.
Athersys
Cleveland, OH
Athersys is a biopharmaceutical and regenerative medicine company that has established a pipeline of therapeutic product development programs in multiple disease areas including pharmaceutical programs focused on obesity and CNS (cognition, attention) and regenerative medicine programs focused on cardiovascular disease, stroke, hematological and immune disorders.
Bayhill Therapeutics
Palo Alto, CA
Biopharmaceutical company focused on the translation of research into therapeutics for the treatment of autoimmune diseases. Bayhill's lead compound, an antigen-specific immunotherapy aimed at treating multiple sclerosis, is currently in Phase I clinical trials. A second antigen-specific compound for Type I diabetes and an oligonucleotide therapeutic are both in late preclinical testing.
BioSyntech
Laval, Quebec
TSX V: BSY
The company specializes in the discovery, development and manufacturing of biotherapeutic thermogels for regenerative medicine and therapeutic delivery. Its platform technology is a family of hydrogels that can be injected or applied to specific sites and which offer beneficial properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds.
BrainCells
San Diego, CA
BrainCells, INC (BCI) is a leading-edge neurogenesis-based drug discovery and development company targeting novel therapies for depression, mood disorders and other CNS diseases. The company is developing a neurogenesis platform for profiling and selecting drug candidates. BCI believes that the platform represents a major improvement in the predictive power of pre-clinical models for CNS disorders and will facilitate a paradigm shift in the way CNS drugs are discovered.
CeNeRx BioPharma
Cary, NC
CeNeRx focuses on identifying and developing promising therapeutics to treat diseases related to neurotransmitters -- therapeutic priorities include anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, Parkinson's and Alzheimer's disease.
Cequent Pharmaceuticals
Cambridge, MA
Early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.
Cognetix
Salt Lake City, UT
Biopharmaceutical company that is developing peptide therapeutics for the treatment of epilepsy, pain and anesthesia. The company's research and development efforts are focused on conopeptides which are peptides derived from the venom of predatory sea snails. Cognetix has corporate collaborations in place with Medtronic, Inc. and Elan Corporation plc.
CoLucid Pharmaceuticals
Indianopolis, IN
CoLucid Pharmaceuticals is a development stage biopharmaceutical company developing and discovering therapeutics that will be used to treat neurological dysfunctions. CoLucid develops pharmaceuticals with novel mechanisms of action to treat migraine headaches. The company also possesses a robust chemistry platform that will produce unique bifunctional neuromodulators to treat indications such as Alzheimer's disease.
Dynogen Pharmaceuticals
Waltham, MA
Neuroscience-based drug discovery and development company targeting novel therapies for genitourinary and gastrointestinal disorders. Dynogen is leveraging its world-class expertise in the development and utilization of predictive in vitro and in vivo models, along with its understanding of the biology and neurobiology underlying these conditions, to discover and develop new drugs for GU and GI disorders.
EBM Solutions
Nashville, TN
Acquired by HealthGate Data Corp. in 2003
Evidence-based medical solutions provider that partners high-quality health and medical information with ongoing monitoring and analysis of healthcare organizations' online initiatives. HealthGate's consumer health information is URAC-accredited and the evidence-based clinical guidelines are backed by independent medical review support through affiliations with Duke University Medical Center, Emory University School of Medicine, Oregon Health and Science University, and Vanderbilt University Medical Center.
Emerald BioAgriculture
Lansing, MI
Bioagriculture company developing, manufacturing and marketing biological and biochemical agents to improve crop yields, enhance quality, combat disease and fight pests. The company's lead product, AuxiGro®, is the first yield increasing biochemical to be registered by the California Department of Pesticide Regulation.
FlowCardia
Sunnyvale, CA
Medical device company that is developing a catheter for the treatment of chronic total occlusions (CTOs) of coronary arteries. Utilizing a technology known as high frequency mechanical recanalization, the company's CROSSER™ System safely and quickly breaks up CTOs allowing subsequent stent placement or balloon angioplasty and avoiding the trauma of cardiac surgery. Clinical trials are underway in Europe.
Genstruct
Cambridge, MA
Systems biology drug discovery company that deploys its mechanism discovery platform, Molecular Epistemics™, independently and in partnerships with pharmaceutical companies to streamline drug discovery and improve clincial trial design and implementation. Pappas Ventures II originally invested in Incellico, Inc. which was acquired in July 2003 by Genstruct.
Gentis
Wayne, PA
Gentis is a biomaterials and orthopedics company that has developed and is testing a potentially breakthrough, non-fusion technology for the treatment of spinal disc disease. Gentis's lead product is DiscCell, a proprietary, injectable, in-situ polymerizing spinal nucleus augmentation technology.
LEAD Therapeutics
San Francisco, CA
LEAD Therapeutics is a chemistry-driven small-molecule drug discovery company, pursuing validated drug targets with rapid and efficient lead-optimization strategies. The company is leveraging its highly experienced, U.S.-based scientific team with high-quality, lower-cost chemistry capabilities in China.
LipoScience
Raleigh, NC
Diagnostic company utilizing nuclear magnetic resonance (NMR) spectroscopy to measure the size and quantity of lipoprotein particles in blood. The company's NMR LipoProfile® blood test is intended to provide a better indication of the risk of developing cardiovascular heart disease than the standard cholesterol test measurements of 'good' and 'bad' cholesterol. The company currently markets and sells the NMR LipoProfile test to physicians, other healthcare professionals, diagnostic laboratories and clinical research clients.
MethylGene
Montreal, Quebec
TSE: MYG
Biopharmaceutical company focused on the discovery, development and commercialization of novel enzyme inhibitors for the treatment of cancer and infectious diseases. The company uses functional genomics to validate enzyme targets and uses rational drug design and medicinal chemistry to design, synthesize and optimize enzyme inhibitors.
Optherion
New Haven, CT
Optherion, Inc. is an early-stage biotechnology company that is developing products to treat and diagnose dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system. Optherion's proprietary technologies are based on recent scientific discoveries linking certain genes to AMD.
Panacos Pharmaceuticals
Watertown, MA
Nasdaq: PANC
Merged with V.I. Technologies in 2005
Panacos is a biopharmaceutical company engaged in the discovery, development and commercialization of small molecule drugs to treat or prevent serious infectious disease. The Company has an expanding pipeline of promising anti-infective drug candidates for major markets with significant, unmet medical needs. The Company's lead antiviral product is PA-457, the first in a new class of drugs to treat HIV infection discovered by Panacos scientists currently in Phase 2 clinical trials.
Plexigen
Cary, NC
Company developing an innovative, proprietary 3-D biochip to significantly enhance the capacity, efficiency, accuracy and automation of gene screening. The technology was originally developed at North Carolina State University.
Plexxikon
Berkeley, CA
Drug discovery company that utilizes a structural proteomics approach to discover novel pharmaceuticals. Using high-throughput X-ray crystallography, the company screens for novel chemical backbones known as scaffolds. The scaffolds are then co-crystallized with drug targets leading to high quality drug leads. Plexxikon has collaborations in place with Genentech, Inc. and Wyeth Pharmaceuticals.
Sensys Medical
Chandler, AZ
Developer of non-invasive technology for blood glucose monitoring. Once cleared by the Food and Drug Administration, the technology will provide a painless method to collect data for proactive use in controlling diabetes.
Spherics
Mansfield, MA
Pharmaceutical company focused on applying its oral drug delivery platform to develop products with improved therapeutic profiles
Syndax Pharmaceuticals
Waltham, MA
Syndax is an oncology-focused biopharmaceutical company that is developing novel therapies in optimized, mechanistically driven combination regimens.
TargeGen
San Diego, CA
Biopharmaceutical company focusing on treatments for cardiovascular diseases and cancer. The company is developing small molecule kinase inhibitors that suppress vascular permeability and vascular proliferation associated with these diseases.
TyRx
Monmouth Junction, NJ
Medical device company developing a range of drug-eluting implantable devices based on proprietary tyrosine polymer technology licensed from Rutgers University. The company's lead product is AIGIS-Rx™, an antibiotic-eluting mesh envelope into which pacemakers and defibrillators can be inserted prior to surgical implantation, thereby reducing the risk of post-procedure infection.
X-Ceptor Therapeutics
San Diego, CA
Nasdaq: EXEL
Acquired by Exelixis in 2004
Genomics-based drug discovery company focused on the discovery and development of novel therapeutics across various therapy areas. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis' development pipeline currently covers cancer and metabolism. Pappas Ventures I was part of the founding investor group that originally invested in X-Ceptor Therapeutics, Inc., which was acquired in October 2004 by Exelixis, Inc.